Core Insights - NeuroBo Pharmaceuticals has signed an exclusive license agreement with MThera Pharma for NB-01, aimed at treating painful diabetic neuropathy, allowing MThera to conduct research and clinical trials, including a potential Phase 3 trial in the U.S. and South Korea [1][2] - The agreement is a strategic move for NeuroBo to focus on the clinical development of its other assets, DA-1726 and DA-1241, while leveraging MThera's expertise in natural medicines and botanical drugs [2] - MThera plans to utilize its SyMthomics platform technology to identify the mechanism of action and active ingredients of NB-01, aiming to advance it into the next phase of clinical development [2] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [4] - DA-1241 is a GPR119 agonist that has shown positive effects on liver inflammation, lipid metabolism, and glucose control in preclinical studies [4] MThera Pharma Overview - MThera Pharma, based in Seoul, South Korea, develops first-in-class botanical drug products using multi-component therapies for chronic diseases like Parkinson's and inflammatory bowel disease [3] - The company's SyMthomics platform integrates AI-based systems biology and bioinformatics to ensure therapeutic consistency and meet FDA requirements [3]
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01